Labcorp Holdings Inc. (LH)
Automate Your Wheel Strategy on LH
With Tiblio's Option Bot, you can configure your own wheel strategy including LH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LH
- Rev/Share 165.6474
- Book/Share 104.8496
- PB 2.427
- Debt/Equity 0.7508
- CurrentRatio 1.5513
- ROIC 0.0636
- MktCap 21056185500.0
- FreeCF/Share 16.6161
- PFCF 15.2493
- PE 24.6808
- Debt/Assets 0.3576
- DivYield 0.0113
- ROE 0.102
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LH | HSBC Securities | Buy | Hold | -- | $260 | July 10, 2025 |
| Initiation | LH | Redburn Atlantic | -- | Buy | -- | $276 | April 2, 2025 |
| Upgrade | LH | Citigroup | Neutral | Buy | $250 | $300 | March 4, 2025 |
| Upgrade | LH | Evercore ISI | In-line | Outperform | $260 | $265 | Jan. 7, 2025 |
| Resumed | LH | Jefferies | -- | Buy | $265 | $275 | Dec. 10, 2024 |
| Initiation | LH | Piper Sandler | -- | Neutral | -- | $235 | Oct. 1, 2024 |
News
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
LH inks new agreement to acquire BioReference Health's oncology and related clinical testing services businesses.
Read More
Should Labcorp Stock Stay in Your Portfolio Right Now?
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
LH stays on investors' radar owing to its strong focus on high-growth areas and pursuing strategic acquisitions.
Read More
Here's Why Labcorp (LH) is a Strong Value Stock
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
Labcorp® Plasma CompleteTM offers oncologists a highly sensitive and specific genomic profiling solution from a simple blood draw BURLINGTON, N.C. , Feb. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the clinical availability of Labcorp® Plasma CompleteTM , a circulating tumor DNA (ctDNA)-based comprehensive genomic profiling solution for patients with advanced solid tumors.
Read More
Labcorp Holdings: Focus On Core Strengths For Future Growth, Initiate At 'Hold'
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Positive
Labcorp Holdings Inc., a leader in life sciences and diagnostics, is efficiently managing its financials and focusing on core strengths for long-term growth, warranting a “Hold” rating. Competitive advantages include large scale, diversified business model, strong industry relationships, and operational efficiency, driving strong revenue and margin expansion. Recent strategic initiatives like the Fortrea spin-off, Invitae acquisition, and SYNLAB stake enhance Labcorp's core business and future growth prospects.
Read More
Why Labcorp (LH) is a Top Momentum Stock for the Long-Term
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
About Labcorp Holdings Inc. (LH)
- IPO Date 1990-03-29
- Website https://www.labcorp.com
- Industry Medical - Equipment & Services
- CEO Adam H. Schechter
- Employees 60900